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Introduction.SmallnoncodingRNAshaveimportantregulatoryfunctionsindiﬀerentcellpathways.Itisbelievedthatmostofthem
mainly play role in gene post-transcriptional regulation in the cytoplasm. Recent evidence suggests miRNA and siRNA activity
in the nucleus. Here, we show distinct genome-wide sub-cellular localization distribution proﬁles of small noncoding RNAs in
human breast cancer cells. Methods. We separated breast cancer cell nuclei from cytoplasm, and identiﬁed small RNA sequences
using a high-throughput sequencing platform. To determine the relationship between miRNA sub-cellular distribution and cancer
progression, we used microarray analysis to examine the miRNA expression levels in nucleus and cytoplasm of three human cell
lines,onenormalbreastcelllineandtwobreastcancercelllines.LogisticregressionandSVMwereusedforfurtheranalysis.Results.
The sub-cellular distribution of small noncoding RNAs shows that numerous miRNAs and their isoforms (isomiR) not only locate
to the cytoplasm but also appeare in the nucleus. Subsequent microarray analyses indicated that the miRNA nuclear-cytoplasmic-
ratio is a signiﬁcant characteristic of diﬀerent cancer cell lines. Conclusions. Our results indicate that the sub-cellular distribution is
important for miRNA function, and that the characterization of the small RNAs sub-cellular localizome may contribute to cancer
research and diagnosis.
1.Introduction
Cancer is a syndrome with complex pathogeny and is one of
the principal causes of mortality all over the world [1]. When
a normal cell transforms to a tumor cell, a variety of genes
change their expression characteristics. It is believed that the
deregulation of oncogenes and tumor-suppressor-genes is
one of the major causes of tumorigenesis. Present knowledge
suggests that deregulation of gene expression consists of at
least two aspects, abnormal gene expression levels and irreg-
ular localization of the gene products (i.e., mRNAs, proteins
or noncoding RNAs). With the exception of a few reports
concerned with the subcellular localization of the gene pro-
d u c t so fp 5 3a n dB R C A 1[ 2, 3], most focus has been on
expression levels. Although recently an increasing number
of noncoding RNA (ncRNA) (e.g., miR-21, miR-155, miR-
122, and others) have been shown to act as oncogenes (on-
comirs) or tumor-suppressor genes [4, 5], the sub-cellular
localization of noncoding RNAs is not well known, and
little eﬀort have been directed at analyzing the sub-cellular
localization regulation of microRNAs and other important
noncoding RNAs [6].
Small noncoding RNAs, including microRNAs (miR-
NAs),short interfering RNAs (siRNAs),and Piwi-interacting
RNAs (piRNAs), are important regulators of gene expression
[7]. miRNAs and siRNAs guide sequence-speciﬁc cleavage,
deadenylation, and translational repression of target mRNAs
[8], whereas piRNAs appear to be speciﬁcally expressed
in testes [9] and control retrotransposition activity in the
mammalian germ line [10, 11]. MicroRNAs are cleaved from
70- to 100-nucleotide pre-miRNA hairpins, yielding 19-
to 25-nucleotide long mature miRNAs [12]. One example
of miRNA involvement in tumorigenesis is represented by
miR-10b, which initiates tumour invasion and metastasis in
breast cancer, one of the most common malignancies among2 International Journal of Cell Biology
women worldwide [13]. Early investigations suggested that
mature microRNAs have a cytoplasmic localization in the
cell. However, several lines of evidence point to the existence
ofactivenuclearRNAipathwaysinhumancellnuclei.Recent
research indicate that siRNA-induced transcriptional gene
silencing through DNA methylation occur in various human
cell types [14, 15], and small nuclear RNAs (e.g., 7SK and
U6)havebeendownregulatedbyectopicsiRNAactivity[16].
The presence of the RNA-induced silencing complex (RISC)
component AGO2 in the nucleus has been demonstrated
[17], and at least one microRNA (miR-29b) is present in the
nucleus [18]. However, the mechanisms by which miRNAs
and RISCs are programmed to localize in and function in the
nucleus are not known in detail [19].
In order to investigate the sub-cellular distribution of
small noncoding RNAs and its relation to cancer, three dif-
ferent cell lines were used: normal breast cells (MCF-10A),
noninvasive breast cancer cells (MCF-7), and invasive breast
cancercells (MDA-MB-231). Small RNA proﬁles from nuclei
and cytoplasm of MDA-MB-231 were obtained using the Il-
lumina high-throughput sequencing platform (Solexa) [20].
Based on the small RNA sequences detected in MDA-MB-
231, a RNA microarray was designed to obtain a sub-cellular
localization proﬁle of the small RNAs in the three cell lines,
and miRNA “nuclear-cytoplasmic ratios” (NCRs) were cal-
culated for all three cell lines to explore whether the changes
in sub-cellular localization relate to cancer progression.
2.MaterialsandMethods
2.1. Small RNA Library Preparation and High-Throughput
Sequencing. The human breast cancer cell lines MCF-7,
MDA-MB-231 and the human mammary epithelial cell line
MCF-10A were obtained from the American Type Culture
Collection (ATCC, Rockville, MD, USA). MCF-10A cells
were cultured in DMEM-F12 (Life Technologies) supple-
mented with 5% horse serum, 0.5μg/mL hydrocortisone
(Sigma), 10μg/mL insulin (Sigma), 20ng/mL epidermal
growth factor (Sigma), 100μg/mL penicillin and 100μg/mL
streptomycin. Other cells were grown in DMEM (Life
Technologies) supplemented with 100μg/mL penicillin,
100μg/mL streptomycin, and 10% heat-inactivated FBS at
37◦Cinahumidiﬁedatmospherecontaining5%CO2.T rans-
fection of tumor cells with miRNAs (3.5 × 106)w a sp e r -
formed with lipofectamine 2000 (Invitrogen) according to
the manufacturer’s instructions.
Sub-cellular fractioning was executed according to the
sub-cellular fractionation protocol provided by Abcam
[21]. Total RNA was extracted from the sub-cellular frac-
tions with Trizol (Invitrogen). Immediately following RNA
precipitation, construction of small RNA cDNA libraries
for SOLEXA high-throughput sequencing was initiated
from 20μg each of the nuclear and cytoplasmic small
RNA isolates. The RNA was size-fractioned using 15%
TBU PAGE, and a gel fragment corresponding to RNAs
of 17 to 30 nucleotides was excised, and the RNA
eluted. The eluted RNAs were precipitated with ethanol
and resuspended in diethyl pyrocarbonate-treated deion-
ized water. The gel-puriﬁed small RNAs were ligated
sequentially ﬁrst to 5  end and then to 3  end RNA
oligonucleotide adapters using T4 RNA ligase (10units/μL)
( P r o m e g a ,M a d i s o n ,W I ) .T h e5   end RNA adapter
(5 GUUCAGAGUUCUACAGUCCGACGAUC3 ) possessed
5  and 3  hydroxyl groups, whereas the 3  RNA adapter (5 -
pUCGUAUGCCGUCUUCUGCUUGidT-3 ) possessed a 5 
monophosphate and a 3  inverted deoxythymidine (idT).
The small RNAs were ﬁrst legated to the 5  RNA adapter,
and the ligation products were gel-eluted and ligated to the
3  RNA adapter. The ﬁnal ligation products were then used
as templates in a reverse transcription (RT) reaction using
the RT-primer (5 CAAGCAGAAGACGGCATACGA3 )a n d
Superscript II reverse transcriptase (Invitrogen, Carlsbad,
CA, USA) according to the instructions of the Illumina man-
ufacturer. This was followed by a 15 cycle PCR ampliﬁcation
step using the PCR reverse (5 -AATGATACGGCGACC-
ACCGACAGGTTCAGAGTTCTACAGTCCGA-3 )a n df o r -
ward (5 -CAAGCAGAAGACGGCATACGA-3 )p r i m e r sa n d
Phusion hot-start high-ﬁdelity DNA polymerase (New Eng-
land Biolabs, Cambridge, MA, USA). All oligonucleotides
were provided by Illumina (San Diego, CA, USA). Lastly,
the ampliﬁcation products were separated by electrophoresis
on a 6% polyacrylamide gel in TBE buﬀer and eluted,
precipitated using ethanol, and resuspended in nuclease-free
water. The puriﬁed PCR products were quantiﬁed on the
Agilent DNA 1000 chip and diluted for sequencing on the
Illumina 1G.
2.2. Small RNA Genomic Mapping and Annotation. All the
sequences were aligned to the human reference genome hg17
(retrieved from the University of California, Santa Cruz
(UCSC)) web site [22] using Mega BLAST (version 2.2.9),
andonlytheonesofwhichmorethan90%ofthenucleotides
mapped to the genome sequences were retained. For each
read, the longest alignment was determined, and the shorter
reads that mapped to the same position were stored as an
isoforms group. The mapped small RNA sequences were
used for further analysis if the corresponding transcript was
detected at least three times. The information used for an-
notation derived from RefSeq genes, RepeatMasker, and sno
tables from the UCSC web site. Sequences of all known
miRNA genes were downloaded from miRBase release 12.0,
and other known ncRNAs were downloaded from the most
relevant databases [23–26].
A BLAST (blastn program) search was then performed
on the downloaded material using our small RNA sequences
as queries, and hits were deﬁned with a 90% match criterion
(including indels). Sequences overlapping annotations from
the downloaded databases were classiﬁed into the following
classes in the listed order: miRNA, piRNA, tRNA, rRNA,
snoRNA, snRNA, other known noncoding RNA, genomic
repeats, and known protein-coding gene (exon or intron).
Mapped sequences that did not overlap any of these anno-
tations were automatically classiﬁed as “unknown”.
2.3. Novel MicroRNAs Prediction. Candidate miRNA gene
sequences were identiﬁed from uniquely mapped small RNA
sequences (reads ≥ 3) which lack annotations in above data-
bases.Then240bpofgenomicsequenceﬂankingeachsideofInternational Journal of Cell Biology 3
these candidate sites was extracted. A previously published
method (“MiRscan” [27]) was used to score the candidate
pre-miRNA sequences and identify the most likely pre-
miRNA hairpins and candidate microRNAs.
MiRscanwastrainedwiththeknownhumanmicroRNAs
and pre-miRNA sequences in miRBase (release 12.0) to gain
miRNA score matrix. According to this score matrix, each
candidate pre-miRNA was assigned a score to indicate simi-
larity to hairpins of experimentally veriﬁed human microR-
NAs. With a cutoﬀ score of 7.200 (P-value < 0.005), 48 novel
microRNAs were obtained from the nucleus and 31 from the
cytoplasm.
2.4. Microarray Assay and Nuclear-Cytoplasmic Ratio Calcu-
lation. The μParaﬂo microRNA microarray assay was used
to determine the miRNA nuclear-cytoplasmic ratio (NCR)
in MDA-MB-231, MCF-7, and MCF-10a cells. Nuclear and
cytoplasmic RNA was extracted as described previously.
Probes were designed corresponding to more than one
thousand of the detected small RNAs in MDA-MB-231, and
nuclear and cytoplasmic small RNA samples were labeled
with Cy5 and Cy3, respectively, thus enabling direct cal-
culation NCR from the signal intensity ratios (for fur-
ther details see Supplemental Methods available online at
doi:10.1155/2012/672462). All data in this work are MIAME
compliant.
2.5. MicroRNA Classiﬁcation Based on NCR. To distinguish
the microRNAs by their expression and localization proﬁle
variation,wedeﬁnedamicroRNAintegrativevariationtrend
between two cell lines (Vθ). Figure 5 shows an example of Vθ
for MCF-10A and MCF-7 (denoted as Vθ c), calculated as
Vθ c = tan(θc) =

ΔN
ΔC

=

NMCF10A −NMCF7
CMCF10A −CMCF7

,( 1 )
where the ΔN = (NMCF-10A − NMCF-7) is the variation in the
nuclear expression intensity of a given microRNA, and the
ΔC = (CMCF-10A −CMCF-7) is the variation in the cytoplasmic
expression intensity of the same microRNA. The ratio of
nuclear to cytoplasmic expression variation thus repre-
sents the microRNA integrative variation trend. For each
microRNA, three variation trends, Vθ a, Vθ b,a n dVθ c were
calculated, representing the variation trends between MCF-
7 and MDA-MB-231, MDA-MB-231 and MCF-10A, MCF-
10A, and MCF-7, respectively. For all microRNAs that
appeared in all the three cell lines, we calculated the Pearson
correlation coeﬃcient for microRNA pairs based on the
vectors (Vθ a, Vθ b,a n dVθ c). The tri-NCR groups were nor-
malized by setting the highest intensity to 100. MicroRNAs
with similar NCR positions in each cell line were grouped
together (e.g., miR-16 and miR-20a, miR-93 and miR106b;
Figure 4).
In Figure 5,“ c” is the variation track from MCF-10A
to MCF-7 of the miR-21. Thus, we deﬁned the integrative
variation trends for miR-21 from MCF-10A to MCF-7 as
Vθ c = tan(θc) =

ΔN
ΔC

=

NMCF7 −NMCF10A
CMCF7 −CMCF10A

. (2)
F o re a c hm i c r o R N A s ,i ne a c hc e l ls t a t e ,( Vθ) has at least two
characteristics, the expression intensity and the sub-cellular
localization. Here, we deﬁne the microRNA expression
intensity in the cell as
r =

N2
intensity +C2
intensity,( 3 )
and the microRNA sub-cellular localization (NCR) proﬁle
parameter in the cell as
theta = arctan

Nintensity
Cintensity

,( 4 )
where Nintensity and Cintensity are the nuclear and cytoplasmic
expression intensities, respectively.
2.6. SVM Classiﬁcation of Diﬀe r e n tB r e a s tC a n c e rC e l lL i n e s .
In a further analysis, we explored the connection between
the cancer development states and the microRNA NCRs. In
order to simultaneously utilise both the expression intensity
and the NCR of the microRNAs in each cell line, we
transferred the rectangular coordinate to angular coordi-
nates (Figure 5 shows an example for rMCF-7 and θMFC7).
Figure 3(a) demonstrates the angular coordinate of a given
miRNA. A binary classiﬁcation SVM (ksvm in the R package
kernel lab) was used to further classify them. Using the built-
in linear kernel function in the package which maps the
vector to a higher dimensional space, a hyperplane can be
found so that the distance from it to the nearest data point
on each side (microRNAs from MDA-MB-231 and MCF-
7) is maximized. At the same time, the contour lines of the
values generated by the kernel function are nearly vertical,
suggesting that the decisive variable of the kernel is NCR,
and that the NCR value can be used to distinguish the breast
cancer cell lines (Figure 3(b)).
2.7. Statistic Analysis of the MicroRNA Isoform Size Distri-
bution. To test if sequence length is signiﬁcantly correlated
with miRNA sub-cellular localization, a Boolean variable (1
and 0 indicating that a sequence is located in the nucleus
and cytoplasm, resp.) was used as the response variable and
the length of the sequences in each dataset as the predictor.
The logistic regression showed the signiﬁcance level of the
coeﬃcientestimateforthepredictor(P<2e−16).Foronenu-
cleotide increase in sequence length, the log odds of the
sequence staying in nucleus increased by 0.124. A post-chi-
square test of the diﬀerence between the current model and
the null model also show the logistic model ﬁtted well (P<
2.12e−16). These results suggested that the size of mature
microRNAs and their isoforms could be correlated with the
sub-cellular localization of the mature microRNAs.
3. Results
3.1. Genomewide Detection and Annotation of Nuclear and
Cytoplasmic Small RNAs in Human Breast Cancer Cells.
High-throughput sequencing of small RNA samples in
MDA-MB-231humanbreastcancercellsproduced3,053,680
and 3,216,761 unﬁltered small RNA reads from nuclear4 International Journal of Cell Biology
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Figure 1: Distribution of small RNA sequences. (a) Distribution of 7498 cytoplasmic small RNA sequences. (b) Distribution of 15255
nuclear small RNA sequences. Almost one-ﬁfth of nuclear small RNAs was annotated as piRNAs.
and cytoplasmic RNA isolates, respectively (Supplemen-
tal Figure S1). After ﬁltering and mapping (Supplemental
Table S1), the nuclear and cytoplasmic samples yielded
15,255 and 7,498 reliable small RNA sequences, respectively
(Figure 1). Among these, we found 5,260 and 2,695 small
RNAs that could be mapped to unique genomic positions
(Supplemental Table S2). The 5,260 nuclear sequences could
be divided into three roughly equal fractions consisting of
1,646 sequences (31%) annotated as small ncRNAs, 1,808
sequences (34%) corresponding to tRNAs, rRNAs, other
ncRNAs and mRNA fragments, and 1,806 sequences (34%)
corresponding to nonannotated sequences. The 1,806 non-
annotated sequences may represent novel miRNAs, piRNAs,
siRNAs, or possibly new types of small RNAs [28]. More
than 60% of the uniquely mapped small RNAs loci are inter-
genic and about 15% originated from coding gene introns
(Supplemental Table S3 and Figure S2). Close to 3% (171
sequences)ofthenuclearuniquelymappedsequencesarean-
notated as piRNAs, which previously have only been report-
ed to be expressed in mammalian germline cells [11]. Using
all mapped sequences from the nuclear sample (15,255) as
queries in a BLAST search against all known piRNAs, we
found that 2,871 of the sequences can be mapped to 118
known piRNAs (Supplemental Table S4).
To distinguish putative novel miRNAs and endo-siRNAs
[29, 30], which are generally 18–25 nucleotides long, from
possible piRNAs which are slightly longer (26–30nt), we
divided the RNAs into a short and a long fraction. Analysis
oftheshortfractionlociwithin-houseandpublicalgorithms
(see Section 2) identiﬁed 48 putative novel microRNA genes
that are expressed in the MDA-MB-231 cell line (Sup-
plemental Table S5). Recent results from high-throughput
sequencing have demonstrated that experimentally obtained
miRNAs sequences frequently deviate from their corre-
sponding reference sequences in miRBase, suggesting the
existenceofmultiplematuremiRNAvariants(isomiRs)[20].
Similar variation at the 5  and 3  ends of known miRNAs
was also observed in our study (Supplemental Table S6). Al-
though the possible functions of miRNA isoforms are
unknown, it is evident that 5  end variation in a miRNA
could alter the active seed sequence and lead to diﬀerences
in target speciﬁcity [31].
3.2. MicroRNA and Isoform Size Correlates with Subcellular
Localization. M i c r o R N A sa n dR I S C sh a v eb e e nf o u n di n
both cytoplasm and nucleus, but the mechanisms specifying
their sub-cellular localization and transport are not clear.
A hexanucleotide element directing miRNA nuclear import
appears only to be relevant for miR-29b [18]. To clarify what
possibly determines the microRNA sub-cellular localization
proﬁle, we compared small RNA sequences annotated as
known microRNAs, obtained from nuclear and cytoplasmic
extracts of MDA-MB-231 cells. No speciﬁc sequence motif
was found that could explain the diﬀerence in sub-cellular
localization, but the sequence size distributions of the two
sub-cellular miRNAs population diﬀered clearly. To further
quantify this diﬀerence, the lengths of all the isoforms of
every known microRNA in the nuclear and cytoplasmic
data sets were collected, and a logistic regression showed a
signiﬁcant (P<2.2×10
−16)d i ﬀerence in length distribution
ofmiRNAsandisomirsfoundinthenuclearandcytoplasmic
compartments (see Section 2; Figure 2).
3.3.MicroRNAsShowVaryingSub-CellularExpressionProﬁles
in Human Breast Cancer Cell Lines. Translocation between
nucleus and cytoplasm appears to be a functional aspect ofInternational Journal of Cell Biology 5
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certain oncogenes and tumour suppressors, such as p53 and
BRCA1[2,3].Inordertoinvestigatenuclearandcytoplasmic
distributions of small RNAs in normal breast cells (MCF-
10A), noninvasive breast cancer cells (MCF-7) and invasive
breast cancer cells (MDA-MB-231), we designed a small
RNA microarray based on the small RNA sequences detected
in MDA-MB-231 to obtain a localization proﬁle of the
small RNAs. We calculated their “nuclear-cytoplasmicratio”
(NCR) and found that the NCR values of a large number
of miRNAs varied considerably between diﬀerent cell lines
(Supplemental Table S7). It suggested that the miRNA sub-
cellular localization may be correlated with the breast cancer
progression. In some cases, the same microRNA presented
similar overall expression levels in the three breast cell lines
but showed distinct diﬀerences in their sub-cellular expres-
sion concentrations. Taken together, these data suggestedInternational Journal of Cell Biology 7
Table 1: Expression level and sub-cellular distributions of miRNA in two breast cancer cell lines.
miRNA MDA-MB231 MCF-7
Total Reads∗ NCR (log2) N reads∗∗ C reads∗∗ Total Reads∗ NCR (log2) N reads∗∗ C reads∗∗
Hsa-miR-27b 56565 1.73 43463 13102 24084 −1.09 7700 16384
Hsa-miR-29a 5811 3.05 5185 626 1976 −1.93 410 1565
Hsa-miR-29c 172226 ∼0 86113 86113 23259 −1.93 4835 18424
The sequencing data for MDA-MB231 and MCF-7 in GSE16579 were downloaded from the Gene Expression Omnibus (GEO). Adapter sequences were
removed from reads. Filtered reads with lengths from 18nt to 25nt were annotated using MirBase, v.16.0 by BLAST with at 100% identify (0 mismatch).
∗Total Reads obtained from GSE16579.
∗∗N-a n dC-reads are reads number in nucleus and cytoplasm, respectively. These were calculated from Total Reads and the NCR.
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thatanintegrativeapproachconsideringboththeoveralland
sub-cellularexpressionproﬁlesofmiRNAsmightbevaluable
in distinguishing diﬀerent tumor cell lines (Figure 3).
4. Discussion
MicroRNA expression proﬁles are gaining importance as a
means of accurately distinguishing diﬀerent types of cancers
[1, 32]. When combined with target prediction, they can
also be used to identify miRNA regulated pathways [33],
and in some cases diﬀerential miRNAs expression has been
shown to inﬂuence the suppression of certain types of cancer
[34]. Recently, evidence indicates that miRNAs not only are
present in the cytoplasm but also in the nucleus. [35, 36].
Our ﬁndings provide new clues for identifying functions of
cancer-related noncoding RNA genes. The spatial distribu-
tion of miRNAs, as indicated by their NCR patterns, may
serve as future markers of cancer and malignancy states.
Meanwhile,basedonourobservationthatthesmallRNA
sizedistributionsarediﬀerentinthenuclearandcytoplasmic
cellular compartments, and the present hypothesis that the
Argonaute protein or the RISC is involved in shuttling small
RNAs between the nucleus and cytoplasm, we would like
to suggest the following hypothesis that loading of longer
miRNAs or siRNAs onto AGO2 might induce structural
changesintheRISCorotherwiseprovidethesignaltospecify
the import of the RNA-protein complex into the nucleus.
In the nucleus, miRNAs or siRNAs might act as guiding
molecules in various functional pathways such as alternative
splicing and epigenetic sites recognizing [37]. Moreover,
since miRNAs in the cytoplasm generally target sites in the 3 
UTRofmRN As,and3   UTRcis-elementshavebeenreported
to control the sub-cellular localization of mRNAs [38], the
aberrant localization of miRNA may subsequently result in
abnormal sub-cellular localization of mRNAs or proteins.
In animal testis cells, piRNAs have been shown to
lead epigenetic modiﬁcation to chromatin, including DNA
methylation and histone modiﬁcation [39]. However, the
biological functions of short small RNAs (<25nt) in the
nucleus are still unclear. The fact that a number of miRNAs
showed diﬀerent sub-cellular distributions in diﬀerent cell
lines implies that “traditional” miRNA expression proﬁles
maynotbeacompletereﬂectionoftheactualmiRNAexpres-
sion patterns. Furthermore, while cytoplasmic miRNAs may
regulate gene expression at the posttranscription level by
binding to 3  UTR of mRNAs, current target predication
methods based on 3  UTR-seed matching may not be rele-
vant to miRNAs that predominantly appear in the nucleus.
The NCR values of many miRNAs varied among three
cell lines, as well as the expression of a number of miRNAs
(Table 1). The expression level of miR-27b in the nucleus
of MDA-MB231 cell line was almost 2 fold higher than in
MCF-7 cell line; however, the cytoplasmic miR-27b levels
were similar in the two cell lines. Moreover, the higher miR-
27b expression in nucleus of MDA-MB231 cell line was
in accordance with the result present above. Similarly, the
nuclear expression of miR-29c was also signiﬁcantly higher
(∼17.8 fold) in MDA-MB231 than in MCF-7, compared to
only about 4.7 fold diﬀerence in cytoplasmic expression.
In contrast, the sub-cellular distribution of miR-29a was
opposite to that of miR-29c in these two cell lines. In
the MDA-MB231 cell line, the nuclear expression of miR-
29a was almost 12.6 fold higher than in MCF-7, while
the MDA-MB231 cytoplasmic expression miR-29a level was
less than half that of MCF-7. These results suggest that in
addition to altered protein sub-cellular distributions, the
sub-cellular localization of regulative RNA molecules may
also be important in cancer. Although the mechanism by
which these nuclear small RNAs aﬀect cancer is poorly
understood, the sub-cellular miRNA distributions may be a
future tool in cancer cell research and diagnosis (Figure 4).8 International Journal of Cell Biology
5. Conclusions
Using high-throughput sequencing and microarray tech-
niques, we have identiﬁed 79 new miRNAs candidates and
revealed distinct miRNA sub-cellular localization patterns
in three diﬀerent breast cancer cell lines. Moreover, the
length distribution of miRNA isoforms varies in the diﬀerent
sub-cellular fraction, longer and shorter isoforms tending
towards nuclear and cytoplasmic localizations, respectively.
These facts suggest that the miRNA sub-cellular localization
may play an important role in cancer diagnosis and research.
Abbreviation
NCR: Nuclear-cytoplasmic ratio.
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